Journal article
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes
Abstract
BACKGROUND: Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec.
METHODS: We …
Authors
Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr P-M; Lange M; Brown-Frandsen K
Journal
The New England Journal of Medicine, Vol. 377, No. 8, pp. 723–732
Publisher
Massachusetts Medical Society
Publication Date
August 24, 2017
DOI
10.1056/nejmoa1615692
ISSN
0028-4793